You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
濟南高新(600807.SH):艾克韋生物不會納入公司2021年財務報表、公司尚無生物醫療領域相關人員及技術儲備
格隆匯 01-13 19:04

格隆匯1月13日丨濟南高新(600807.SH)公佈股票交易異常波動公吿,公司股票於2022年1月11日、1月12日、1月13日連續三個交易日收盤價格漲幅偏離值累計超過20%,屬於股票交易異常波動。

經公司自查並向公司控股股東核實,除公司已披露的公司下屬子公司擬收購山東艾克韋生物技術有限公司(簡稱“艾克韋生物”)部分股權事項、公司下屬子公司擬將持有的NQM Gold 2 Pty Ltd100%股權出售給關聯方山東玉龍黃金股份有限公司(簡稱“玉龍股份”)下屬子公司外,截至公吿披露日,不存在應披露而未披露的重大事項。

相關事項及風險提示:

1、公司收購艾克韋生物部分股權,存在以下事項及風險:

(1)營業收入、市場份額佔比小,毛利率低於同行業水平。2021年1月-9月,艾克韋生物核酸檢測試劑類收入2030萬元,佔公司同期營業收入的2.60%,佔比較小,艾克韋生物核酸檢測試劑類產品毛利率約15%,低於同行業主要上市公司平均水平,且其全部客户均在國內,市場份額佔比較小。

(2)目前股權過户登記尚未完成,艾克韋生物不會納入公司2021年財務報表。目前,艾克韋生物股權過户登記手續尚未完成,不會納入公司2021年財務報表合併範圍,不會對公司2021年財務報表業績產生影響。

(3)公司暫無生物醫療領域相關人員、技術儲備,存在整合風險:艾克韋生物經營範圍與公司主營業務存在較大差異,公司尚無生物醫療領域相關人員、技術儲備,併購後公司能否對艾克韋生物實施有效整合和管理尚存在不確定性。

(4)經營未達預期、業績承諾不能實現的風險:如艾克韋生物未來經營未達預期,導致業績承諾無法實現,將影響公司的整體經營業績和盈利水平。

2、公司擬出售NQM Gold 2 Pty Ltd100%股權事項,存在以下風險:

(1)不確定性風險:交易尚需通過有權機構及監管部門同意,能否實施存在不確定性;

(2)公司業績短期下滑風險:公司出售NQM Gold 2 Pty Ltd股權後存在短期內影響公司經營業績的風險。

3、公司近一年及一期的歸母淨利潤均虧損,且同比大幅下滑:2020年公司實現歸屬於上市公司股東的淨利潤為-82,498.99萬元,同比下降1,406.93%,2021年1-9月實現歸屬於上市公司股東的淨利潤為-16,519.23萬元,同比下降11,011.96萬元,近一年又一期公司業績處於虧損;

4、累計漲幅大幅偏離行業同期水平:股票短期漲幅高於同期上證指數和同行業指數(偏離上證指數26.52%,偏離同行業指數27.72%),面臨自身經營業績、股票漲幅波動較大等風險,敬請廣大投資者注意二級市場交易風險,理性決策,審慎投資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account